Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis

Trial Profile

Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2015

At a glance

  • Drugs TC 6499 (Primary)
  • Indications Diabetic gastroparesis
  • Focus Therapeutic Use
  • Sponsors Targacept
  • Most Recent Events

    • 16 Apr 2015 According to a Targacept media release, status changed from active, no longer recruiting to completed.
    • 16 Apr 2015 Top-line results published in the Media Release.
    • 16 Apr 2015 Primary endpoint (The change in gastric emptying half-time determined for each treatment relative to placebo after single dose administration of study drug in each arm) has not been met, according to Targacept media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top